MX2017012449A - Tratamiento del dolor. - Google Patents

Tratamiento del dolor.

Info

Publication number
MX2017012449A
MX2017012449A MX2017012449A MX2017012449A MX2017012449A MX 2017012449 A MX2017012449 A MX 2017012449A MX 2017012449 A MX2017012449 A MX 2017012449A MX 2017012449 A MX2017012449 A MX 2017012449A MX 2017012449 A MX2017012449 A MX 2017012449A
Authority
MX
Mexico
Prior art keywords
individual
pain treatment
pain
managing
managing pain
Prior art date
Application number
MX2017012449A
Other languages
English (en)
Inventor
Alexander Barden Julian
Original Assignee
Biosceptre Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901215A external-priority patent/AU2015901215A0/en
Application filed by Biosceptre Uk Ltd filed Critical Biosceptre Uk Ltd
Publication of MX2017012449A publication Critical patent/MX2017012449A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método de tratamiento del dolor en un individuo, que incluye las siguientes etapas: proporcionar un individuo que necesita tratamiento del dolor; administrar un anticuerpo anti-receptor P2X7 al individuo; tratando de ese modo el dolor en el individuo.
MX2017012449A 2015-04-02 2016-04-01 Tratamiento del dolor. MX2017012449A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901215A AU2015901215A0 (en) 2015-04-02 Pain treatment
AU2015901216A AU2015901216A0 (en) 2015-04-02 Pain treatment
PCT/AU2016/050249 WO2016154683A1 (en) 2015-04-02 2016-04-01 Pain treatment

Publications (1)

Publication Number Publication Date
MX2017012449A true MX2017012449A (es) 2018-02-21

Family

ID=57003686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012449A MX2017012449A (es) 2015-04-02 2016-04-01 Tratamiento del dolor.

Country Status (9)

Country Link
US (1) US20180037650A1 (es)
EP (1) EP3277726A4 (es)
JP (2) JP6790062B2 (es)
CN (1) CN107614528A (es)
AU (1) AU2016240410B2 (es)
BR (1) BR112017020783A8 (es)
CA (1) CA2980788A1 (es)
MX (1) MX2017012449A (es)
WO (1) WO2016154683A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
US20240368282A1 (en) * 2021-09-01 2024-11-07 Biosceptre (Aust) Pty Ltd Methods and compositions for stimulating immune activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100022531A1 (en) * 2005-09-01 2010-01-28 Renovis, Inc. Novel compounds as p2x7 modulators and uses thereof
WO2007109201A2 (en) * 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
CN102143978B (zh) * 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) * 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) * 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) * 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
AU2013269606B2 (en) * 2012-06-01 2018-05-17 Ablynx N.V. P2X7 receptor antagonists and agonists
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.

Also Published As

Publication number Publication date
EP3277726A1 (en) 2018-02-07
JP7096558B2 (ja) 2022-07-06
AU2016240410A1 (en) 2017-09-28
US20180037650A1 (en) 2018-02-08
WO2016154683A1 (en) 2016-10-06
EP3277726A4 (en) 2018-08-22
AU2016240410B2 (en) 2021-09-16
JP2018514583A (ja) 2018-06-07
CA2980788A1 (en) 2016-10-06
JP6790062B2 (ja) 2020-11-25
BR112017020783A8 (pt) 2022-08-02
JP2021014460A (ja) 2021-02-12
CN107614528A (zh) 2018-01-19
BR112017020783A2 (pt) 2018-06-26

Similar Documents

Publication Publication Date Title
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
EA201790398A1 (ru) Способы лечения заболевания печени
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
AR095882A1 (es) Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
SA516370641B1 (ar) مركبات حلقية غير متجانسة وطرق لاستخدامها
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
ZA202503387B (en) Semaglutide in medical therapy
MX365403B (es) Peptidos y metodos para usarlos.
MX2017003691A (es) Metodos para tratar lupus eritematoso sistemico usando un anticuerpo de dominio dirigido contra cd28.
TW201613975A (en) Methods for treating multiple myeloma
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
EP3581205A3 (en) Product and method for treating diarrhea
MX2018016103A (es) Metodos para manejar los efectos adversos en poblaciones de pacientes que necesitan una transfusion.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2017012449A (es) Tratamiento del dolor.
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
MX386151B (es) Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.
MX2016011706A (es) Formulaciones de progesterona.
IL252239A0 (en) Chronic pain management methods and hcg therapy
MA40574A (fr) Traitement de maladies fibrotiques
UA89943U (uk) Спосіб прискорення провідності нервово-м'язового імпульсу в спортсменів
UA84302U (ru) Способ коррекции иммунного статуса у больных рекуррентным депрессивным расстройством
IN2014MU01245A (es)